A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 688 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence Into Action MOST POPULAR New Safety Signal for Use of Ibrutinib in Combination with Rituximab... September 15, 2021 EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan July 13, 2023 EMA Recommends Extension of Therapeutic Indications for Irinotecan Hydrochloride Trihydrate April 3, 2024 Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer June 25, 2024 Load more HOT NEWS BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with... Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer...
